Andrew Saunders, MD
27 years of experience in haematology/oncology in the pharmaceutical industry including large pharma companies (Eli Lilly, Hoffman La-Roche, AstraZeneca), oncology companies (Pharmacyclics, Cell Therapeutics, ONO pharmaceuticals), and oncology CROs (Theradex,Nexus/Ockham). Currently he works as CMO of two oncology biotech companies (Cellcentric Limited, RedX Pharma). Saunders successfully led the development and marketing authorisation approval of 2 oncology products: Mabthera® (rituximab) and Evoltra® (clofarabine).
Enrique M. Ocio, PhD, MD
Deputy Medical Hematology Service of the University Hospital of Salamanca. A translational clinician expert in haematological neoplasias. Responsible of development of new antitumor drugs from preclinical to clinical trials in early phases, with a focus on multiple myeloma. Principal investigator in more than 15 clinical trials and responsible of 5 international clinical trials.
Tim Hammond (Toxicology – Professor, BSc, PhD, FRCPath)
35 years of experience in pharmaceutical drug Discovery and Development. He was former Vice President of Safety Assessment in the UK for AstraZeneca, responsible for non-clinical safety development of the full oncology portfolio, including registration of Irressa and Olaparib, among others. He has extensive experience in the selection, early development and registration of modalities intended to be used in oncology. Currently he is an independent consultant.
Joan Alberti (ADME).
15 years of research experience in the Pharmaceutical Industry supporting drug metabolism and pharmacokinetics (DMPK). Project team member at early- and late-phase development phase I, II, and marketing approval, as well as experience at writing the ADME section for IB, IND and NDA regulatory documents. He worked as head of ADME and metabolism at Almirall, and was responsible for ADME at Prodesfarma. Currently he is an independent ADME advisor.
Resu Alloza (CMC – BSc Pharmacist, MBA).
25 years of experience in CMC and pharmaceutical development with special attention to peptides and proteins formulations and complex parenteral products. She has successfully lead several peptide formulation projects from preclinical to clinical phases. She has worked as Head of Manufacturing & formulation development (Proretina, Vivia Biotech, Azurebio), formulation team leader (Octoplus), formulation coordinator (Hipra), and formulation manager (IPSEN).
Lidia Canovas (Regulatory Affairs – BSc Pharmacist, MBA, ASPHALION). Lidia Canovas has 19 years of experience in regulatory Affairs at Asphalion, where she is currently General Manager of regulatory Affairs. ASPHALION is an International Scientific and Regulatory Affairs consultancy firm. Founded in 2000, ASPHALION currently consist in 70 professional consultants with backgrounds in Pharmacy, Chemistry, Biology, Biochemistry, Biotechnology, Medicine and Veterinary Medicine. ASPHALION offers comprehensive services for Drug Development and Regulatory Affairs to Pharma, Biotech and Medical Devices companies.
José M López-Picazo, PhD, MD
Medical Oncologist at University Clinic of Navarra and assistant Professor at Medical School of the University of Navarra, Spain, with main dedication to lung cancer and head and neck cancer. As a researcher he has focused on predictive and prognostic factors aimed at precision oncology practice. He has been principal investigator in more than 20 clinical trials, including new drugs or combination therapies.
Fernando Lecanda, PhD, Professor (University of Navarra).
Graduated in Pharmacy and Ph.D. in Physiology. Dr. Lecanda is Head of the Adhesion and Metastasis Laboratory at the Center for Applied Medical Research (CIMA) and Full Professor in Cell Biology (University of Navarra. In the past 15 years he has focused on the mechanisms of lung cancer bone metastases.